Madrigal Pharmaceuticals, Inc.
MDGL· Nasdaq
Released May 6, 2026, before the open
10-Q filed May 6, 2026, 36 days after period end · 0001628280-26-030947
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Revenue | $311.34M | $137.25M | $0.00 | $0.00 |
| Net Income | -$94.39M | -$73.24M | -$147.54M | -$76.90M |
| EPS Diluted |
Madrigal Pharmaceuticals, Inc. · CIK 1157601 · Engraved from SEC EDGAR
| -$3.25 |
| -$2.61 |
| -$7.38 |
| -$4.23 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.